1-4 of 4
Dale Miles
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

Kyriakos P. Papadopoulos, Josep Tabernero, Ben Markman, Amita Patnaik, Anthony W. Tolcher, José Baselga, Weiliang Shi, Coumaran Egile, Rodrigo Ruiz-Soto, A. Douglas Laird, Dale Miles, Patricia M. LoRusso
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (9): 2445–2456.
https://doi.org/10.1158/1078-0432.CCR-13-2403
Published: 30 April 2014
View article titled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

Joseph Paul Eder, Geoffrey I. Shapiro, Leonard J. Appleman, Andrew X. Zhu, Dale Miles, Harold Keer, Belinda Cancilla, Felix Chu, Suzanne Hitchcock-Bryan, Laurie Sherman, Stewart McCallum, Elisabeth I. Heath, Scott A. Boerner, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (13): 3507–3516.
https://doi.org/10.1158/1078-0432.CCR-10-0574
Published: 01 July 2010
View article titled, A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
Open the PDF for A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2 in another window
Journal Articles

Motexafin Gadolinium: A Redox Active Drug That Enhances the Efficacy of Bleomycin and Doxorubicin

Richard A. Miller, Kathryn W. Woodburn, Qing Fan, Intae Lee, Dale Miles, George Duran, Branimir Sikic, Darren Magda
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (10): 3215–3221.
Published: 01 October 2001
View article titled, Motexafin Gadolinium: <subtitle>A Redox Active Drug That Enhances the Efficacy of Bleomycin and Doxorubicin</subtitle>
Open the PDF for Motexafin Gadolinium: <subtitle>A Redox Active Drug That Enhances the Efficacy of Bleomycin and Doxorubicin</subtitle> in another window
Journal Articles

A Phase I Single-Dose Trial of Gadolinium Texaphyrin (Gd-Tex), a Tumor Selective Radiation Sensitizer Detectable by Magnetic Resonance Imaging

David I. Rosenthal, Pamela Nurenberg, Carlos R. Becerra, Eugene P. Frenkel, David P. Carbone, Bert L. Lum, Richard Miller, Julie Engel, Stuart Young, Dale Miles, Markus F. Renschler
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (4): 739–745.
Published: 01 April 1999
View article titled, A Phase I Single-Dose Trial of Gadolinium Texaphyrin (Gd-Tex), a Tumor Selective Radiation Sensitizer Detectable by Magnetic Resonance Imaging
Open the PDF for A Phase I Single-Dose Trial of Gadolinium Texaphyrin (Gd-Tex), a Tumor Selective Radiation Sensitizer Detectable by Magnetic Resonance Imaging in another window